About: Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A.     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • In two tumour models, 3MC-induced MHC class I + sarcoma Mc12 HPV 16 E6/E7 oncogene-induced MHC class I - carcinoma MK16, the effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and GM-CSF was investigated. In both types of tumours, the combined chemoimmunotherapy can inhibit tumour progression more effectively than GM-CSF therapy or chemotherapy alone.
  • In two tumour models, 3MC-induced MHC class I + sarcoma Mc12 HPV 16 E6/E7 oncogene-induced MHC class I - carcinoma MK16, the effectiveness of combined chemoimmunotherapy with ifosfamide derivative CBM-4A and GM-CSF was investigated. In both types of tumours, the combined chemoimmunotherapy can inhibit tumour progression more effectively than GM-CSF therapy or chemotherapy alone. (en)
Title
  • Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A.
  • Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. (en)
skos:prefLabel
  • Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A.
  • Chemoimmunotherapy of cancer: potentiated effectiveness of granulocyte-macrophage colony-stimulating factor and ifosfamide derivative CBM-4A. (en)
skos:notation
  • RIV/68378050:_____/01:23010376!RIV/2003/AV0/A23003/N
http://linked.open.../vavai/riv/strany
  • 1371;1374
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • P(GA301/00/0114), P(GA301/01/0985), P(GA312/99/0542), P(IAA7052002), P(NC5526), P(NC5900), Z(AV0Z5052915)
http://linked.open...iv/cisloPeriodika
  • 6
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 675516
http://linked.open...ai/riv/idVysledku
  • RIV/68378050:_____/01:23010376
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • chemoimmunotherapy; - murine; - neoplasms (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GR - Řecká republika
http://linked.open...ontrolniKodProRIV
  • [54CFA84730B7]
http://linked.open...i/riv/nazevZdroje
  • Oncology Reports
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...ocetUcastnikuAkce
http://linked.open...nichUcastnikuAkce
http://linked.open...vavai/riv/projekt
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 8
http://linked.open...iv/tvurceVysledku
  • Bieblová, Jana
  • Bubeník, Jan
  • Indrová, Marie
  • Mikyšková, Romana
  • Šímová, Jana
  • Šmahel, M.
  • Jandlová, Táňa
  • Pajtasz-Piasecka, E.
  • Radzikowski, C.
  • Vonka, V.
  • Glazman-Kusnierczyk, H.
http://linked.open...n/vavai/riv/zamer
issn
  • 1021-335X
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 35 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software